<DOC>
	<DOCNO>NCT00004024</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Combining different type biological therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness biological therapy follow surgery radiation therapy treat patient primary recurrent astrocytoma oligodendroglioma .</brief_summary>
	<brief_title>Biological Therapy Following Surgery Radiation Therapy Treating Patients With Primary Recurrent Astrocytoma Oligodendroglioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy immunotherapy irradiate autologous tumor cell vaccine adoptive immunotherapy , term time progression median one-year survival , patient primary recurrent malignant astrocytoma oligodendroglioma . - Determine immunogenicity malignant glioma patient treat regimen . OUTLINE : Patients stratify accord extent disease , extent antigen-specific response vaccination , performance status ( 0 vs 1 ) , prior therapy ( yes v ) , gender . Patients undergo tumor resection week 1 . Patients without recurrent disease receive local radiotherapy week 2-8 . Beginning week 10-12 , patient vaccinate irradiated autologous tumor cell sargramostim ( GM-CSF ) receive GM-CSF alone intradermally vaccination site daily 4 day . Patients revaccinated 4 week later may receive 3 additional vaccination every 2 week response detect . Patients undergo peripheral blood mononuclear cell collection week 14 follow monoclonal antibody OKT3-activated T lymphocytes IV 1-6 hour alternate interleukin-2 IV every day 5 dose 10 day begin week 16 . Treatment continue absence disease progression unacceptable toxicity . Patients may receive one additional course immunotherapy . Patients follow 1 week , monthly 3 month , every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Muromonab-CD3</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven grade II , III , IV astrocytoma oligodendroglioma Evidence primary recurrent tumor MRI Resectable disease At least 20,000,000 viable cell obtain surgical specimen use immunization part study PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 0 1 Life expectancy : At least 6 month Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least low limit normal No active recent uncontrolled bleeding Hepatic : Bilirubin normal SGOT great 2 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Renal : Creatinine normal Other : Able weaned steroid Negative stool guaiac No impaired immunity No uncontrolled diabetes No active uncontrolled infection No serious disease No malignancy within past 5 year except curatively treat basal squamous cell skin cancer carcinoma situ cervix No psychological , familial , sociological , geographical condition would preclude compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent chemotherapy except progressive disease Endocrine therapy : See Disease Characteristics Radiotherapy : Radium implant allow Surgery : Not specify Other At least 1 week since prior therapy recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
</DOC>